Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02000102

Enrollment

Registered

2013-12-03

Start date

2013-09-30

Completion date

2014-09-30

Last updated

2014-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Edema

Brief summary

Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.

Interventions

DRUGIntravitreal Injection of Aflibercept

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Those patients with diabetic macular edema switched to aflibercept from bevacizumab and/or ranibizumab -

Exclusion criteria

None \-

Design outcomes

Primary

Measure	Time frame
Visual Acuity	1 year

Secondary

Measure	Time frame
Central Subfield Thickness on Optical Coherence Tomography	1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026